Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OABI vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OABI Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–5 Matrix Metrics)

OABI Overall Winner 6-Pillar Tally: OABI 4 – 1 LCTX (1 Tie) Matrix Metrics: OABI 5 – 5 LCTX

As of Nov 20, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. OABI 45.5/100 HOLD), OABI captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-92.9% vs. -280.3% operating margin) and revenue trajectory (+78.3% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: OABI trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.9); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OABI vs LCTX
OABI NASDAQ Head-to-Head Winner
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$4.66
-7.36% 1D
Market Cap $733.7M
TTM Revenue $40M
Forward P/E N/M
Beta / 30D Vol 1.24β · 60% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.9 · SMA20: $5.03 · SMA50: $4.82
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (OABI 4 – 1 LCTX)

Columns: Metric · OABI · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue 18.1x 15.9x
2. Growth & Scale OABI
Revenue Growth (YoY) +78.3% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $40M $11M
Market Cap $733.7M $207.4M
3. Profitability & Quality OABI
Gross Margin 97.7% -95.0%
Operating Margin -92.9% -280.3%
Net Profit Margin -108.1% 16.2%
Return on Equity (ROE) -16.5% 4.3%
4. Balance Sheet & Cash Flow OABI
Cash Generation (TTM) $2.4M -$24M
Cash Flow Margin 5.9% N/A
Net Cash / Leverage $4.7M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OABI
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 101.7% (14th %ile) 0.0% (<1st %ile)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OABI (5) vs LCTX (5)
Institutional Metric OABI LCTX Criterion Row Edge
Market Capitalization
Scale
$733.7M $207.4M Larger Scale OABI
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
+78.3% -61.0% Higher Growth OABI
Operating Margin (TTM)
Profitability
-92.9% -280.3% Higher Margin OABI
Net Profit Margin
Profitability
-108.1% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-16.5% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
81% ($1–$5) 0% ($1–$2) Stronger Trend OABI
Beta / 30D Volatility
Risk Regime
1.24β · 60% Vol 1.39β · 79% Vol Lower Realized Risk OABI
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$40M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.7% -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.1x EV/Rev 10.64x PEG · 15.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.4M ($4.7M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OABI +19.12 pp
OABI: -2.51% · LCTX: -21.63%
3M Horizon OABI +28.12 pp
OABI: -1.06% · LCTX: -29.18%
6M Horizon OABI +116.47 pp
OABI: +75.85% · LCTX: -40.62%
1Y Horizon OABI +237.28 pp
OABI: +182.42% · LCTX: -54.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OABI Revenue LCTX Revenue OABI Op. Margin LCTX Op. Margin Margin Leader
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 N/A $0M N/A -1448.4% LCTX
FY2021 $30M $0M -102.5% -1133.6% OABI
FY2022 $60M $10M -45.1% -153.2% OABI
FY2023 $30M $10M -203.2% -276.5% OABI
FY2024 $30M $10M -282.3% -226.1% LCTX
FY2025 $20M $10M -369.5% -251.6% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OABI CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 101.7%
IV Percentile 14th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OABI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $733.7M market capitalization and -92.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OABI vs LCTX Key Questions & Quantitative Answers

As of Nov 20, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. OABI 45.5/100 HOLD), OABI captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-92.9% vs. -280.3% operating margin) and revenue trajectory (+78.3% vs. -61.0% YoY). Technical & Structure Timing Caution: OABI trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.9); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OABI leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OABI cumulative revenue shifted -33.3% while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.1x EV/Revenue (5.9% FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, OABI carries 101.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.24β · 60% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.